Syntaxin
Engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
Launch date
Market cap
-
Enterprise valuation
€187m (Public information from Jul 2013)
Boulogne-Billancourt Île-de-France (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 |
|---|---|---|---|
| Revenues | <1m | <1m | <1m |
| % growth | - | 38 % | (66 %) |
| EBITDA | <1m | (<1m) | - |
| % EBITDA margin | 10 % | (4 %) | - |
| Profit | <1m | (<1m) | - |
| % profit margin | 8 % | (4 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $10.4m | Series A | |
$32.0m | Series B | ||
$29.0m | Series C | ||
$206m Valuation: $206m | Acquisition | ||
| Total Funding | €64.9m | ||